Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.58 |
| ▸ | PTGES | O14684 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | FOS | P01100 | 1/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319431 | 0.95 | MEN1 (0.53) | ALOX5PTGESPPARGMEN1ALDH1A1 | |
| SCHEMBL20184152 | 0.86 | ALDH1A1 (0.58) | MEN1ALDH1A1KMT2AMAPTFOS | |
| SCHEMBL7814561 | 0.86 | ALDH1A1 (0.58) | MEN1ALDH1A1KMT2AMAPTFOS | |
| SCHEMBL7814564 | 0.86 | ALDH1A1 (0.58) | MEN1ALDH1A1KMT2AMAPTFOS | |
| SCHEMBL3544382 | 0.86 | ALDH1A1 (0.61) | MEN1ALDH1A1KMT2AMAPTFOS | |
| SCHEMBL3544381 | 0.86 | ALDH1A1 (0.61) | MEN1ALDH1A1KMT2AMAPTFOS | |
| SCHEMBL3549405 | 0.86 | ALDH1A1 (0.61) | MEN1ALDH1A1KMT2AMAPTFOS | |
| SCHEMBL3145879 | 0.85 | EPHX2 (0.49) | ALOX5PTGESPPARGMEN1ALDH1A1 | |
| SCHEMBL3145890 | 0.85 | EPHX2 (0.49) | ALOX5PTGESPPARGMEN1ALDH1A1 | |
| SCHEMBL6367852 | 0.83 | ALOX5 (0.58) | ALOX5PTGESPPARGAPEX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | ALOX5 3216/4885PTGES 1450/4885PPARG 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.